Quality & complianceCompany release

Celularity to purify and test Vesalius's Peptual peptide APIs under exclusive US deal

🇺🇸 Celularity Inc (CELU) · Thu 29 Oct 2026

The agreement covers work at Celularity's New Jersey site, but supply to US compounders depends on FDA adding the peptides to its bulk drug substances list.

Celularity Inc. and Vesalius Longevity Labs announced on 29 October 2026 an exclusive agreement under which Celularity will carry out downstream purification, processing and testing of Vesalius's Peptual-branded peptide active pharmaceutical ingredients (APIs). The work will take place at Celularity's facility in Florham Park, New Jersey, using processes the companies describe as cGMP-focused.

The companies plan to supply eligible APIs to licensed US compounding pharmacies, but only if the US Food and Drug Administration adds the relevant peptides to its list of bulk drug substances for compounding. That step would follow the agency's consideration of recommendations from its Pharmacy Compounding Advisory Committee.

The release stresses the limits of the arrangement. The peptides are not FDA-approved, and GLP-1 and weight-loss peptides are excluded from the scope. The agreement does not in itself authorise any commercial release of the materials.

By way of context, compounders generally may use bulk drug substances in certain compounded preparations only where the substance meets conditions under US law, including inclusion on an FDA list. The companies' plans are therefore tied to the outcome of that regulatory process.

What it means for your team

  • Commercial supply under this deal is contingent on FDA listing of the relevant peptides for compounding; the agreement alone authorises nothing.
  • Quality teams at compounding pharmacies should note that the peptides are unapproved and that cGMP-focused processing is claimed for the downstream steps at the New Jersey site.
  • GLP-1 and weight-loss peptides fall outside the scope, so the arrangement does not address that segment.
  • Regulatory watchers should follow Pharmacy Compounding Advisory Committee recommendations and any FDA decision on the bulk drug substances list.

Company's press release (SEC filing): Celularity Inc ↗

Article written by VigiEye from the official source (Celularity Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Quality & compliance All →